Mazdutide is a once-weekly injectable dual receptor agonist targeting both the GLP-1 and glucagon receptors, for chronic weight management, it is the world’s first approved dual GCG/GLP-1 agonist for obesity.
Dual Action: Combines GLP-1 receptor activation (lowers blood sugar, slows digestion, curbs appetite) with glucagon receptor activation (increases energy expenditure and fat oxidation).
Indications: Used for chronic weight management in adults with obesity (BMI ≥ 28) or overweight (BMI ≥ 24) with weight-related comorbidities, as well as type 2 diabetes management.
Efficacy and Clinical Data
Weight Loss clinical trials show significant, superior weight reduction compared to placebos and standard doses of alternatives like semaglutide.
Metabolic Impact, it demonstrates improvements in waist circumference, blood pressure, lipid profiles, and glycemic control (HbA1c).
Side Effects: Primarily mild-to-moderate, transient gastrointestinal events like nausea, diarrhea, and vomiting, mostly occurring during dose escalation.
Clinical observations note an increase in resting heart rate, consistent with other incretin-based therapies.